Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Paulo M. Hoff(Translational Research in Oncology), Shethah Morgan(AstraZeneca (United Kingdom)), Laura Brooks(University of North Carolina at Chapel Hill), David M. Wilson(AstraZeneca (Singapore)), Maria Taboada(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK)
Cited by 64
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score
|PLoS Medicine|2017|410
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303